Ovid Therapeutics Inc [NASDAQ: OVID] traded at a low on Wednesday, posting a -3.74 loss after which it closed the day’ session at $0.74.
The results of the trading session contributed to over 336114 shares changing hands. Over the past one week, the price volatility of Ovid Therapeutics Inc stands at 12.09% while the volatility over the past one month is 11.05%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for OVID stock reached $52.81 million, with 70.69 million shares outstanding and 57.57 million shares in the current float. Compared to the average trading volume of 826.12K shares, OVID reached a trading volume of 336114 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Ovid Therapeutics Inc [OVID]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OVID shares is $3.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OVID stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Ovid Therapeutics Inc shares, keeping their opinion on the stock as Perform, with their previous recommendation back on June 18, 2024. While these analysts kept the previous recommendation, B. Riley Securities raised their target price to Buy. The new note on the price target was released on April 30, 2024, representing the official price target for Ovid Therapeutics Inc stock. Previously, the target price had yet another raise to $9, while H.C. Wainwright analysts kept a Buy rating on OVID stock.
The Average True Range (ATR) for Ovid Therapeutics Inc is set at 0.19, with the Price to Sales ratio for OVID stock in the period of the last 12 months amounting to 112.37. The Price to Book ratio for the last quarter was 0.67, with the Price to Cash per share for the same quarter was set at 1.27.
How has OVID stock performed recently?
Ovid Therapeutics Inc [OVID] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.48. With this latest performance, OVID shares dropped by -75.35% in over the last four-week period, additionally sinking by -77.58% over the last 6 months – not to mention a drop of -78.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OVID stock in for the last two-week period is set at 21.98, with the RSI for the last a single of trading hit 21.53, and the three-weeks RSI is set at 23.98 for Ovid Therapeutics Inc [OVID]. The present Moving Average for the last 50 days of trading for this stock 2.5406, while it was recorded at 0.7766 for the last single week of trading, and 3.1750 for the last 200 days.
Ovid Therapeutics Inc [OVID]: Deeper insight into the fundamentals
Ovid Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.47 and a Current Ratio set at 10.47.
Insider trade positions for Ovid Therapeutics Inc [OVID]
The top three institutional holders of OVID stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in OVID stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in OVID stock with ownership which is approximately 5.1238%.
